1. 1. Takae K, Nagata M, Hata J, Mukai N, Hirakawa Y, Yoshida D, et al. Serum uric acid as a risk factor for chronic kidney disease in a Japanese community: The Hisayama Study. Circ J 2016; 80: 1857–1862.
2. 2. Kansui Y, Ohtsubo T, Goto K, Sakata S, Ichishima K, Fukuhara M, et al. Association of serum uric acid with blood pressure in Japanese men: Cross-sectional study in work-site group. Circ J 2011; 75: 2827–2832.
3. 3. Fagugli RM, Gentile G, Ferrara G, Brugnano R. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol 2008; 70: 523–526.
4. 4. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25–32.
5. 5. Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J 2013; 77: 2043–2049.